(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 83.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.46%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.3%.
Lenz Therapeutics's revenue in 2026 is $21,475,000.On average, 9 Wall Street analysts forecast LENZ's revenue for 2026 to be $608,612,044, with the lowest LENZ revenue forecast at $338,711,298, and the highest LENZ revenue forecast at $819,693,908. On average, 9 Wall Street analysts forecast LENZ's revenue for 2027 to be $2,024,789,744, with the lowest LENZ revenue forecast at $726,689,693, and the highest LENZ revenue forecast at $3,299,136,015.
In 2028, LENZ is forecast to generate $4,321,239,773 in revenue, with the lowest revenue forecast at $1,736,665,198 and the highest revenue forecast at $8,082,883,237.